Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)201.44
  • Today's Change3.85 / 1.95%
  • Shares traded1.12m
  • 1 Year change-21.52%
  • Beta-0.0537
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Income statement Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
REVENUE AND GROSS PROFIT
Total revenue9,83610,17310,982
OPERATING EXPENSES
Cost of revenue total2,4091,9421,942
Selling, general and admin. expenses, total2,5762,4302,702
Depreciation/amortization241246252
Unusual expense(income)343(505)815
Other operating expenses, total(24)(233)(75)
Total operating expense8,2236,1018,141
Operating income1,6124,0722,841
Other, net(3.5)(10)(5.6)
INCOME TAXES, MINORITY INTEREST AND EXTRA ITEMS
Net income before taxes1,2973,5921,745
Provision for income taxes13563353
Net income after taxes1,1622,9591,693
Minority interest(0.4)85(172)
Net income before extra. Items1,1613,0471,556
Total extraordinary items------
Net income1,1613,0471,556
Inc.avail. to common excl. extra. Items1,1613,0471,556
Inc.avail. to common incl. extra. Items1,1613,0471,556
EPS RECONCILIATION
Basic/primary weighted average shares145145149
Basic/primary eps excl. extra items8.022110
Basic/primary eps incl. extra items8.022110
Dilution adjustment------
Diluted weighted average shares146146150
Diluted eps excl. extra items7.972110
Diluted eps incl. extra items7.972110
COMMON STOCK DIVIDENDS
DPS - common stock primary issue------
Gross dividend - common stock000
PRO FORMA INCOME
Pro forma net income------
Interest expense, supplemental247247254
SUPPLEMENTAL INCOME
Depreciation, supplemental254272236
Total special items343(505)815
NORMALISED INCOME
Normalized income before taxes1,6403,0872,560
Effect of special items on income taxes36(89)24
Income tax excluding impact of special items17154476
Normalized income after tax1,4692,5432,484
Normalized income avail. to common1,4682,6312,347
Basic normalized EPS101816
Diluted normalized EPS101816
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.